Population pharmacokinetics of humanized monoclonal antibody HuCC49ΔCH2 and murine antibody CC49 in colorectal cancer patients

Journal of Clinical Pharmacology

Volumn 47, Issue 2, 2007, Pages 227-237

  Fang, Lanyan ^a   Holford, Nicholas H G ^c   Hinkle, George ^a   Cao, Xianhua ^a   Xiao, Jim J ^d   Bloomston, Mark ^b   Gibbs, Seth ^a   Al Saif, Osama Habib ^b   Dalton, James T ^a   Chan, Kenneth K ^a   Schlom, Jeffery ^e   Martin Jr , Edward W ^b   Sun, Duxin ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

^d AMGEN INC   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Bayesian estimation; Population pharmacokinetics; RIGS

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CC49 I 125; MONOCLONAL ANTIBODY HUCC49DELTACH2 I 125; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BAYES THEOREM; BODY WEIGHT; CIRCULATION; CLINICAL TRIAL; COLORECTAL CANCER; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COVARIANCE; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; STATISTICAL MODEL;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; COLORECTAL NEOPLASMS; FEMALE; GLYCOPROTEINS; HUMANS; IODINE RADIOISOTOPES; MALE; MICE; MIDDLE AGED; MODELS, BIOLOGICAL; RADIOIMMUNODETECTION; TUMOR MARKERS, BIOLOGICAL;

EID: 33846408629     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270006293758     Document Type: Article

References (36)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005 ; 55: 10-30.
2. Arnold MW, Schneebaum S, Berens A, et al. Radioimmunoguided surgery challenges traditional decision making in patients with primary colorectal cancer. Surgery. 1992 ; 112: 624-629.
3. Nieroda CA, Mojzisik C, Sardi A, et al. Radioimmunoguided surgery in primary colon cancer. Cancer Detect Prev. 1990 ; 14: 651-656.
4. Johnson VG, Schlom J, Paterson AJ, et al. Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. Cancer Res. 1986 ; 46: 850-857.
5. Klug TL, Sattler MA, Colcher D, Schlom J. Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 72) on a novel pancarcinoma antigen (TAG-72). Int J Cancer. 1986 ; 38: 661-669.
6. Molinolo A, Simpson JF, Thor A, Schlom J. Enhanced tumor binding using immunohistochemical analyses by second generation anti-tumor-associated glycoprotein 72 monoclonal antibodies versus monoclonal antibody B72.3 in human tissue. Cancer Res. 1990 ; 50: 1291-1298.
7. Cohen AM, Martin EW Jr, Lavery I, et al. Radioimmunoguided surgery using iodine 125 B72.3 in patients with colorectal cancer. Arch Surg. 1991 ; 126: 349-352.
8. Sickle-Santanello BJ, O'Dwyer PJ, Mojzisik C, et al. Radioimmunoguided surgery using the monoclonal antibody B72.3 in colorectal tumors. Dis Colon Rectum. 1987 ; 30: 761-764.
9. Martin EW Jr, Mojzisik CM, Hinkle GH Jr, et al. Radioimmunoguided surgery using monoclonal antibody. Am J Surg. 1988 ; 156: 386-392.
10. Kim JA, Triozzi PL, Martin EW Jr. Radioimmunoguided surgery for colorectal cancer. Oncology (Williston Park). 1993 ; 7: 55-60.
11. Nieroda CA, Mojzisik C, Hinkle G, Thurston MO, Martin EW Jr. Radioimmunoguided surgery (RIGS) in recurrent colorectal cancer. Cancer Detect Prev. 1991 ; 15: 225-229.
12. Nag S, Martinez-Monge R, Nieroda C, Martin E Jr. Radioimmunoguided- intraoperative radiation therapy in colorectal carcinoma: a new technique to precisely define the clinical target volume. Int J Radiat Oncol Biol Phys. 1999 ; 44: 133-137.
13. Martinez-Monge R, Nag S, Nieroda CA, Martin EW. Iodine-125 brachytherapy in the treatment of colorectal adenocarcinoma metastatic to the liver. Cancer. 1999 ; 85: 1218-1225.
14. Arnold MW, Young DM, Hitchcock CL, et al. Staging of colorectal cancer: biology vs. morphology. Dis Colon Rectum. 1998 ; 41: 1482-1487.
15. Nieroda CA, Arnold MW, Barbera-Guillem E, Martin EW. Lymphadenectomy in colorectal carcinoma [in German]. Chirurg. 1998 ; 69: 717-724.
16. Nag S, Martinez-Monge R, Mills J, et al. Intraoperative high dose rate brachytherapy in recurrent or metastatic colorectal carcinoma. Ann Surg Oncol. 1998 ; 5: 16-22.
17. Sampsel JW, Hinkle G, Nieroda C, et al. Gamma-detecting probe and autoradiographic studies of radiolabeled antibody B72.3 in CX-1 colon xenografts. J Surg Oncol. 1990 ; 45: 242-249.
18. Sardi A, Nieroda CA, Siddiqi MA, Minton JP, Martin EW Jr. Carcinoembryonic antigen directed multiple surgical procedures for recurrent colon cancer confined to the liver. Am Surg. 1990 ; 56: 255-259.
19. Nieroda CA, Mojzisik C, Sardi A, et al. The impact of radioimmunoguided surgery (RIGS) on surgical decision-making in colorectal cancer. Dis Colon Rectum. 1989 ; 32: 927-932.
20. Sardi A, Agnone CM, Nieroda CA, et al. Radioimmunoguided surgery in recurrent colorectal cancer: the role of carcinoembryonic antigen, computerized tomography, and physical examination. South Med J. 1989 ; 82: 1235-1244.
21. Sardi A, Workman M, Mojzisik C, et al. Intra-abdominal recurrence of colorectal cancer detected by radioimmunoguided surgery (RIGS system). Arch Surg. 1989 ; 124: 55-59.
22. Sardi A, Minton JP, Nieroda C, et al. Multiple reoperations in recurrent colorectal carcinoma: an analysis of morbidity, mortality, and survival. Cancer. 1988 ; 61: 1913-1919.
23. Arnold MW, Schneebaum S, Berens A, et al. Intraoperative detection of colorectal cancer with radioimmunoguided surgery and CC49, a second-generation monoclonal antibody. Ann Surg. 1992 ; 216: 627-632.
24. Finch E Sell L, Arnold D. Cerebral oedema after MDMA ("ecstasy" ) and unrestricted water intake: drug workers emphasise that water is not an antidote to drug. BMJ. 1996 ; 313: 690-690.
25. Contin M, Riva R, Martinelli P, et al. A levodopa kinetic-dynamic study of the rate of progression in Parkinson's disease. Neurology. 1998 ; 51: 1075-1080.
26. Arnold MW, Young DC, Hitchcock CL, Schneebaum S, Martin EW Jr. Radioimmunoguided surgery in primary colorectal carcinoma: an intraoperative prognostic tool and adjuvant to traditional staging. Am J Surg. 1995 ; 170: 315-318.
27. Colcher D, Minelli MF, Roselli M, et al. Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies. Cancer Res. 1988 ; 48: 4597-4603.
28. Larson SB, Day JS, Glaser S, Braslawsky G, McPherson A. The structure of an antitumor C(H)2-domain-deleted humanized antibody. J Mol Biol. 2005 ; 348: 1177-1190.
29. Rogers BE, Roberson PL, Shen S, et al. Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region. Cancer Biother Radiopharm. 2005 ; 20: 502-513.
30. Forero A, Meredith RF, Khazaeli MB, et al. A novel monoclonal antibody design for radioimmunotherapy. Cancer Biother Radiopharm. 2003 ; 18: 751-759.
31. Xiao J, Horst S, Hinkle G, et al. Pharmacokinetics and clinical evaluation of 125I-radiolabeled humanized CC49 monoclonal antibody (HuCC49deltaC(H)2) in recurrent and metastatic colorectal cancer patients. Cancer Biother Radiopharm. 2005 ; 20: 16-26.
32. Aarons L. Population pharmacokinetics: theory and practice. Br J Clin Pharmacol. 1991 ; 32: 669-670.
33. Jonsson EN, Karlsson MO. Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999 ; 58: 51-64.
34. Kloft C, Graefe EU, Tanswell P, et al. Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patients. Invest New Drugs. 2004 ; 22: 39-52.
35. Reff ME, Hariharan K, Braslawsky G. Future of monoclonal antibodies in the treatment of hematologic malignancies. Cancer Control. 2002 ; 9: 152-166.
36. Ghetie V, Popov S, Borvak J, et al. Increasing the serum persistence of an IgG fragment by random mutagenesis. Nat Biotechnol. 1997 ; 15: 637-640.